Actively Recruiting
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Led by NeuroVision Imaging · Updated on 2024-05-07
200
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
CONDITIONS
Official Title
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be 50 years old or older
- Must be eligible for and intend to receive LEQEMBI as standard care treatment
- Must be willing to comply with the study protocol including pupil dilation to at least 3.5 mm for eye imaging
- Patient or legally authorized representative must understand the study purpose and risks and provide informed consent
You will not qualify if you...
- History of acute angle-closure glaucoma or allergic reaction to pupil dilation medication
- Presence of dense cataracts or other significant eye media opacity affecting retinal imaging
- Eye surgery within the past 2 months or current use of eye drops related to recent eye surgery
- Unable or unwilling to comply with study protocol requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sutter Health
Sacramento, California, United States, 95816
Actively Recruiting
Research Team
M
Mieko Chambers, MS
CONTACT
J
Josef Tamory
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here